Hepatitis C Virus Dynamic Transmission Models Among People Who Inject Drugs

References

• Wan H, Adams RL, Lindenbach BD, Pyle AM, James Ou J-H. The in vivo and in vitro architecture of the hepatitis C virus RNA genome uncovers functional RNA secondary and tertiary structures. J Virol. 2022;96(8). doi:10.1128/jvi.01946-21
   Web of Science ®Google Scholar
• Schillie S, Wester C, Osborne M, Wesolowski L; ABR. CDC Recommendations for hepatitis C screening among adults. J Chem Inf Model. 2020;53(9):1689–1699.
   Google Scholar
• World Heath Organization. Updated Reccomendations on Simplified service delivery and diagnostics for hepatitis c infection; 2022. Available from: https://www.who.int/publications/i/item/9789240052697. Accessed February 18, 2023.
   Google Scholar
• EMCDDA. Hepatitis C among drug users in Europe: epidemiology, treatment and prevention. Luxembourg: Publications Office of the European Union; 2016:104. Available from: http://www.emcdda.europa.eu/system/files/publications/2953/TDXD16002ENN_final_web.pdf%0Ahttp://www.emcdda.europa.eu/publications/insights/hepatitis-c-among-drug-users-in-europe_en%0Ahttp://www.emcdda.europa.eu/publications/insights/hepatitis-c-among-drug-. Accessed February 14, 2023.
   Google Scholar
• Karimi SE, Bayani A, Higgs P, et al. Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and meta-analysis. Subst Abuse Treat Prev Policy. 2020;15(1):1–16.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Monitoring and Evaluation for Viral Hepatitis b and c. World Health Organization; 2016:40.
   Google Scholar
• Sector GH. The Public Health Problem of HCV Infection; 2021.
   Google Scholar
• Wendelbeo, AM, Garfe, C, Carabin, H. The benefits of transmission dynamics models in understanding emerging infectious diseases. Am J Med Sci. 2010;340(3) 181–186. doi:10.1097/MAJ.0b013e3181e937ca
   PubMed Web of Science ®Google Scholar
• Simon CM. The SIR dynamic model of infectious disease transmission and its analogy with chemical kinetics. PeerJ Phys Chem. 2020;2:e14. doi:10.7717/peerj-pchem.14
   Google Scholar
• Peng L, Xie P, Tang Z, Liu F. Modeling and analyzing transmission of infectious diseases using generalized stochastic petri nets. Appl Sci. 2021;11(18):8400. doi:10.3390/app11188400
   Google Scholar
• Chen D. Modeling the spread of infectious diseases: a review. Anal Model Spat Temporal Dyn Infect Dis. 2015;2015:19–42.
   Google Scholar
• Buchwald AG, Adams J, Bortz DM, Carlton EJ. Infectious disease transmission models to predict, evaluate, and improve understanding of COVID-19 trajectory and interventions. Ann Am Thorac Soc. 2020;17(10):1204–1206. doi:10.1513/AnnalsATS.202005-501PS
   PubMed Web of Science ®Google Scholar
• Platt L, Stengel CM, Nkurunziza M, et al. Assessing risk of HIV and hepatitis C among people who inject drugs in East Africa: findings from a rapid assessment. J Viral Hepat. 2019;26(7):926–929. doi:10.1111/jvh.13088
   PubMed Web of Science ®Google Scholar
• Shah R, Boucheron P, Mandaliya K, et al. Hepatitis C virus infection in people who inject drugs in Africa. Lancet Infect Dis. 2020;20(3):282–283. doi:10.1016/S1473-3099(20)30049-9
   PubMedGoogle Scholar
• Echevarria D, Gutfraind A, Boodram B, et al. Mathematical modeling of hepatitis C prevalence reduction with antiviral treatment scale- up in persons who inject drugs in metropolitan Chicago. PLoS One. 2015;10(8):1–14. doi:10.1371/journal.pone.0135901
   Web of Science ®Google Scholar
• Khalsa JH, Mathur P. Hepatitis c virus infection in persons who inject drugs in the Middle East and north Africa: intervention strategies. Viruses. 2021;13(7):1–10. doi:10.3390/v13071363
   Web of Science ®Google Scholar
• World Health Organization. Interim guidance for country validation of viral hepatitis elimination [internet]. Geneva: WHO; 2021:1–96. Available from: https://www.who.int/publications/i/item/9789240028395. Accessed February 14, 2023.
   Google Scholar
• Shayan SJ, Nazari R, Kiwanuka F. Prevalence of HIV and HCV among injecting drug users in three selected WHO-EMRO countries: a meta-analysis. Harm Reduct J. 2021;18(1):1–13. doi:10.1186/s12954-021-00505-4
   PubMed Web of Science ®Google Scholar
• Abubakar I, Stagg HR, Cohen T, Rodrigues LC. Transmission-dynamic models of infectious diseases. In: Infectious Disease Epidemiology (Oxford Specialist Handbooks). OUP Oxford; 2016:1–23.
   Google Scholar
• Wang Y, Zhao Z, Wang M, et al. The transmissibility of hepatitis C virus: a modelling study in Xiamen City, China. Epidemiol Infect. 2020;148. doi:10.1017/S0950268820002885
   Web of Science ®Google Scholar
• Kondili LA, Andreoni M, Alberti A, et al. A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions. BMC Infect Dis. 2022;22(1):1–15. doi:10.1186/s12879-022-07042-w
   PubMed Web of Science ®Google Scholar
• Gicquelais RE, Foxman B, Coyle J, Eisenberg MC. Hepatitis C transmission in young people who inject drugs: insights using a dynamic model informed by state public health surveillance. Epidemics. 2019;27(June2018):86–95. doi:10.1016/j.epidem.2019.02.003
   PubMedGoogle Scholar
• Miller-Dickson MD, Meszaros VA, Almagro-Moreno S, Brandon Ogbunugafor C. Hepatitis C virus modelled as an indirectly transmitted infection highlights the centrality of injection drug equipment in disease dynamics. J R Soc Interface. 2019;16(158):20190334. doi:10.1098/rsif.2019.0334
   PubMed Web of Science ®Google Scholar
• Tatara E, Gutfraind A, Collier NT, et al. Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago. PLoS One. 2022;17(3March):1–17. doi:10.1371/journal.pone.0264983
   Google Scholar
• Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Dhersin JS, Yazdanpanah Y. Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review. J Viral Hepat. 2015;22(3):213–229. doi:10.1111/jvh.12337
   PubMed Web of Science ®Google Scholar
• Greenhalgh D, Al- Rashidi N. Modeling the spread of hepatitis C virus amongst people who inject drugs. Eng Rep. 2022;2021:1–30.
   Google Scholar
• WHO. Hepatitis C 24; 2022:1–6.
   Google Scholar
• Jia W, Weng J, Fang C, Li Y. A dynamic model and some strategies on how to prevent and control hepatitis c in mainland China. BMC Infect Dis. 2019;19(1):1–11. doi:10.1186/s12879-019-4311-x
   PubMed Web of Science ®Google Scholar
• Lim JS, Il CS, Ryu S, Il PS. Interpretation of the basic and effective reproduction number. J Prev Med Public Health. 2020;53(6):405–408. doi:10.3961/jpmph.20.288
   PubMedGoogle Scholar
• Zhang S, Zhou Y. Dynamics and application of an epidemiological model for hepatitis C. Math Comput Model. 2012;56(1–2):36–42. doi:10.1016/j.mcm.2011.11.081
   Google Scholar
• Foppa IM, Diekmann O, Heesterbeek JAP, Metz JAJ. The spread of infectious diseases in heterogeneous populations. In: A Historical Introduction to Mathematical Modeling of Infectious Diseases. Vol. 2021. Elsevier; 2017:157–194.
   Google Scholar
• Bailey JR, Barnes E, Cox AL. Approaches, progress, and challenges to hepatitis C vaccine development. Gastroenterology. 2019;156(2):418–430. doi:10.1053/j.gastro.2018.08.060
   PubMed Web of Science ®Google Scholar
• Gastroenterology TL. Editorial the hunt for a vaccine for hepatitis C virus continues. Lancet Gastroenterol Hepatol. 2021;6(4):253. doi:10.1016/S2468-1253(21)00073-X
   PubMed Web of Science ®Google Scholar
• Cox AL. Virus vaccine; 2020:1–16.
   Google Scholar
• Dillon JF, Lazarus JV, Razavi HA. Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatol Med Policy. 2016;1(1):1–10. doi:10.1186/s41124-016-0011-y
   Google Scholar
• Walsh N, Verster A, Rodolph M, Akl EA. WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs. Int J Drug Policy. 2014;25(3):363–371. doi:10.1016/j.drugpo.2014.01.009
   PubMed Web of Science ®Google Scholar
• Delile J-M, de Ledinghen V, Jauffret-Roustide M, et al. Hepatitis C virus prevention and care for drug injectors: the French approach. Hepatol Med Policy. 2018;3(1):1–9. doi:10.1186/s41124-018-0033-8
   PubMedGoogle Scholar